BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Holdings Raised by APG Asset Management N.V.

APG Asset Management N.V. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 587.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 132,987 shares of the biotechnology company's stock after acquiring an additional 113,655 shares during the period. APG Asset Management N.V. owned approximately 0.07% of BioMarin Pharmaceutical worth $8,442,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. TD Private Client Wealth LLC increased its stake in BioMarin Pharmaceutical by 57.4% in the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $36,000. CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 233 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 111.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock valued at $58,000 after purchasing an additional 466 shares during the period. Finally, UMB Bank n.a. raised its stake in shares of BioMarin Pharmaceutical by 260.1% during the 4th quarter. UMB Bank n.a. now owns 1,019 shares of the biotechnology company's stock worth $67,000 after buying an additional 736 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares of the company's stock, valued at approximately $1,212,621.60. This trade represents a 7.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.85% of the company's stock.

Analyst Upgrades and Downgrades

BMRN has been the topic of several analyst reports. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price target on the stock in a research note on Monday, February 24th. Royal Bank of Canada restated a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Wedbush reaffirmed an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Citigroup upped their price target on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Piper Sandler increased their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $94.00.

BioMarin Pharmaceutical Stock Performance

BMRN traded down $0.89 during trading hours on Wednesday, reaching $59.13. The company's stock had a trading volume of 296,508 shares, compared to its average volume of 1,875,917. The company's 50-day moving average is $67.02 and its 200-day moving average is $66.48. The firm has a market cap of $11.28 billion, a PE ratio of 26.88, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. BioMarin Pharmaceutical Inc. has a 52 week low of $52.93 and a 52 week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.